The FDA on November 27, 2023, approved OGSIVEO® for adult patients with progressing Desmoid tumors who require systemic treatment. This is the first approved treatment for Desmoid tumors. OGSIVEO® is a product of SpringWorks Therapeutics, Inc.
Bottom Ad
Advertisement
Subscribe
